Preparation in the original packaging for use in the near future, can be stored at a temperature no higher than 30 ° C for up to 2 weeks. Patients who independently carry out subcutaneous injection of Sandostatin should receive detailed instructions from a doctor or nurse. Before testosterone cypionate injection introduction of the solution should be at room temperature, which helps to reduce discomfort at the injection site.
Do not inject the drug in the same place with short intervals. The vials should be opened just prior to administration of the drug; the unused amount of the solution is discarded. IntravenousBefore using the product for parenteral administration should be carefully inspected for changes in color of the solution and the presence of foreign particles. Sandostatin (octreotide acetate) for 24 hours, maintains physical and chemical stability in a sterile saline solution or 5% glucose solution in water. However, as Sandostatin may affect glucose metabolism, preferably to use saline. The prepared solution maintains physical and chemical stability at a temperature below 25 ° C for at least 24 hours. In order to prevent microbial contamination diluted solutions must be used immediately after preparation. If the solution is not used immediately, it should be stored until its use at a temperature of 2-8 ° C. Before use, the solution should hold at room temperature. The total time between breeding, storage in a refrigerator and the end of the introduction of the solution should not exceed 24 hours. If necessary, the intravenous administration of Sandostatin contents of one ampoule containing 0.5 mg of active substance should be diluted in 60 ml saline and the prepared solution should be administered intravenously. Infusion administration is repeated as often as necessary in accordance with the recommended duration of treatment. Sandostatin may also be administered in lower concentrations.
The main adverse events reported with the use of octreotide were side effects of the digestive, nervous, hepatobiliary system, and metabolic disorders and the development of nutritional deficiencies. In clinical studies, the most frequently observed in the appointment of the drug diarrhea, abdominal pain, nausea, flatulence, headache, formation of stones in the gallbladder, hyperglycaemia and constipation.Also frequently observed dizziness, pain of various localization, violation of colloidal bile stability (formation of cholesterol microcrystals), thyroid disorders (decrease levels of thyrotropin, total and testosterone cypionate injection free thyroxine), soft stool consistency, reduced glucose tolerance, vomiting, asthenia, and hypoglycaemia.
in applying the drug in rare cases, can be observed phenomena resemble acute intestinal obstruction:. progressive abdominal distension, severe epigastric pain, abdominal straining, muscle “protection”
Although the release of fat in the feces can be increased, to date there is no evidence that prolonged treatment with octreotide may lead to nutritional deficiency due to malabsorption (malabsorption).
It was reported about rare cases of acute pancreatitis that developed in the first hours or days p / use of octreotide (Sandostatin) and disappears after discontinuation of the drug. Furthermore, prolonged use of octreotide (Sandostatin) n / k there have been cases of pancreatitis associated with cholelithiasis. According to the data studies on the background of the drug in patients with acromegaly and carcinoid syndrome: observed lengthening the interval QT, axis deviation, early repolarization, low voltage type , the displacement of the transition zone, the early P wave and nonspecific ST-segment and T-wave As in these patients are heart disease, a causal relationship between the use of octreotide and the development of adverse event data is not installed.
From the nervous system : very often – headache; . often – dizziness part of the endocrine system : very often – hyperglycemia; often -gipotireoz / thyroid dysfunction (decreased levels of thyrotropin, total and free thyroxine); hypoglycemia, impaired glucose tolerance. From the hepatobiliary system : very often – cholelithiasis, ie the formation of gallstones; often cholecystitis, a violation of the colloidal stability of bile (the formation of microcrystals of cholesterol), hyperbilirubinemia, elevated liver transaminases. Dermatological reactions: often – itching, rash, hair loss. The respiratory system : often – shortness of breath. On the part of the cardiovascular system : the frequency of bradycardia, sometimes – tachycardia. General disorders and reactions at the injection site:. Very often – pain at the injection site, sometimes – dehydration. On the background of octreotide therapy in clinical practice include the following adverse events irrespective of a causal connection with the use of the drug: Immune system : anaphylactic reactions , allergic reaction / hypersensitivity. Dermatological testosterone cypionate injection reactions: rash. On the part of the hepatobiliary system , acute pancreatitis, acute hepatitis without the phenomena of cholestasis, cholestatic hepatitis, cholestasis, jaundice, cholestatic jaundice, increased alkaline phosphatase, gamma-glutamyltransferase. cardio-vascular system : arrhythmia.